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Since our first report was published in the Hawaii Medical 
Journal in the September 1987 issue and was reprinted in the 
September 1991 special sesquicentennial issue, with the sup-
port of doctors in Hawaii and their referrals, our small team 
has now tested 5,000 people'. DNA analyses have been com-
pleted in over 1,000 people. 
In this hereditary anemia project, many families have bene-
fitted; every participant has been sent a personalized report. 
We have learned valuable lessons about the attitudes and cul-
tures of participants 15 18 about the hematological and clinical 
features of the diverse thalassemias prevalent in Southeast 
Asians1· '· •. 7·12; about how best to detect these and how DNA 
analyses help in confirming or revising diagnoses•· s. 7• 9• 10· 12. 
Couples at risk for having severely affected children have 
been counseled, pregnancies at-risk have been tested". 
The a-thalassemias have major health implications espe-
cially for Filipinos who are the most rapidly growing ethnic 
minority throughout the United States9• 
A special Thalassemia clinic has been established under R 
Wilkinson MD to provide structured care for transfusion-
dependent patients who may need iron-chelation therapy. We 
showed that Hb H disease from loss of 3 a-globin genes is 
usually benign, but Hb H/Constant Spring tends to be transfu-
sion-dependent11. 
Data from this project have greatly improved knowledge 
about the ranges and confidence limits of red cell indices for 
each diagnostic category, with improved interpretations of 
individual results. Extensive experience has been gained in 
using red cell indices and isoelectric focusing to detect a and p 
thalassemia carriers in adults and infants1· 7• 10·12• 
Thalassemia incidences in Laotians and Filipinos were cal-
culated far more accurately than had been done previously'. 
Red cell distribution width and red cell zinc protopophyrin 
by microfluorimetry are shown to be a reliable inexpensive 
way to screen for iron deficiency, except for some overlap 
with P-thalassemia heterozygotes and HB H disease cases. 
Innovative DNA techniques have been created, including 
the first reliable method to look for the Constant Spring muta-
tion6. This uses the polymerase chain reaction (PCR) to ampli-
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fy DNA from the tail end of the ~-globin gene a million-fold 
in a few hours. The technique has been applied to analyze a 
few strands of hair sent from patients in India. 
We have also devised a novel PCR technique to detect the 
most common type of single a-globin gene deletion, introduc-
ing a strategy that is applicable to any large DNA deletion2. 
For rapid fetal detection of a-globin deletions, we have 
developed a multiplex PCR technique to amplify the P-globin, 
a 1 and ~ globin genes simultaneously from drops of blood or 
a few fetal cells. This can be completed in one working day". 
We have adopted 2 useful techniques developed by others. 
One screens for the most common double a-globin deletion, 
using a monoclonal anti-'> antibody on a drop of blood 13• 14. 
Another uses denaturing gradient gel electrophoresis to define 
the dozens of mutations in the ~-gene that produce the ~-tha­
lassemias. 
Data from this project have been presented in national and 
international conferencest-s. 7-to. 12-1"; several articles have been 
published•-7• to-IJ. 16-18 and more are being prepared. I was the 
coordinator and chair of a special workshop on thalassemia 
screening at the Eighth International Congress on Human 
Genetics in Washington, DC, in October, 1991. 
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Indications and Usage: 1. ActMl duodenal ulcer-
tO< up to 8 wee1<s of treatment at a dosage of 300 mg 
h.~ Of 150 mg b.i.d. Most patients heat within 4 weeks. 
2. Maintenance/her.lpy-10< healed duodenal ulcer 
patients at a dosage of I 50 mg h.s. at bedtime. The 
consequences of therapy with Axid lor tonger than 1 
year are oot known. 
3. GaSlrOeSO{Jha(JlliJI reDIJX disease (GE!ID)-10< up 
to 12 wee1<s of treatment ot endoscopically diagnosed 
esophagitis, including erosive and ulcerati"' esophagitis, 
and associated hearttlum at a dosage of 150 mg b.i.d. 
COitraindlcatlon: Known llypefsensitivity to the drug. 
Because cross sensitivity in this class ol oompoonds has 
been obser\'ed, H,-receptor antagonists, including Axid, 
should not be administered to patients with a history 
of hypersensitivity to other H,-receptOf antagonists. 
PrecautloRs: General-1 . Symptomatic respoose to nizatidine therapy does nat preclude the presence 
of gastric malignancy. 
2. Dosage should be reduced in patients with moderate to severe renal insufficiency. 
3. In patients with llOIITlal mnal funcli<Jn and uncomplicated hepatic dysfunclioo. the diS!lOSitioo of 
nizatidine is simoar to that in llOIITlal subjocts. 
Llborafory Tests- False-positive tests iur urobilinogen with Muttistix • may occur during therapy. 
Drug Interactions- No interactions have been observed with theophylline, cfllofdiazepoxide. lorazepam. 
lidocaine, phenytoin, and wartarin. Axid does not inhlbrt the cytochrome P-450 enzyme system; therelofe. 
drug interactions mediated by inhibition of hepatic metabolism are not expected to occur. In patients given 
very high doses (3,900 mg) of aspirin daily, increased serum salicylate levels were seen when nizatidine, 
150 mg b.i.d., was administered concurrently. 
Carcinogenesis. Mutagenesis. lmpairmenl ol Fertility-A 2-year oral carcinogenicity study in rats with 
doses as hig!l as 500 rnglkg/day (aboot 80 times the recommended daily thefapeutic dose) showed no evidence 
ol a carcinogenic elfecl. There was a dose-related increase in the density of enterochromaffin-like (ECl) cet~ 
in the gastric oxyntic mucosa In a 2-year study in mice, there was no evidence ol a carcinogenic effect in male 
mice. altllough hyperplastic nodules of the liver were increased ill the high-dose males as oompared with 
placebo. Female mice given the high dose of Axid (2,000 rng/kglday, about 330 times the human dose) showed 
marginally stltislically significant increases in hepatic carcinoma and hepatic nodular hyperptasja with no 
numetical increase seen in any of the other dose groups.The rate of hepatic carcinoma in the high-dose 
animals was within the historical control limits seen IOf the strain of mice used. The female mice were giverl 
a dose larger than the maximum tolerated dose, as indicated by excessive (30%) weight decrement as compared 
with concurrent contr~ and evidence of mild liver injury (transaminase alevations). The occurrence of a marginal 
finding at high dose only in animals given an excessive and somewhal hepatotoxic dose, with no evidence of a 
carcinogenic elfect in rats, male mice, and female mice (giverl up to 360 rng/kglday, about 60 times the human 
dose). and a negative mutagenicity battery am oot ronsidered evidence at a carcinogenic prrtentiaiiOf Axid. 
Axid was not mutagenic in a battery of tests performed to evaluate its potential genetic toxicity, including 
bacterial mutation tests, unscfleduled DNA synthesis, sister cflromatid excflange, mouse lymphoma assay. 
cflromosome aberration tests, and a mie<onuciOIJs test 
In a 2-generalioo, perinatal and postnatal fertility study in rats, doses of nizatidine up to 650 mgii<Q/day 
produced no adverse effects on the reproductive pe~onmance of parental animals Of their progeny. 
Pregnancy- Teratogenic Effects-Pregnancy Caregory C-Oral reproduclioo studies in rats at doses up 
to 300 times the human dose and in llutcfl Belted rabiJits at doses up to 55 times the human dose revealed no 
evidence of impaired fertility or teratogenic effect; but, at a dose equivalent to 300 times the human dose. 
treated rabbits had abortions, decreased number of live fetuses, and depressed fetal weights. On intravenous 
administration to pregnant New Zealand White rabbits, nizatidine at 20 mg/kg produced cardiac enlargement. 
coarctatioo of the aortic arcfl, and cutarreous edema in 1 fetus, and at 50 mglkg. ~ produced ventricular 
anomaly, distendOO abdomen, spina bifida. hydrocephaly. and enlarged heart in 1 fetus. Thet"e are. however, 
no adequate and weft-controlled studies in pregnant women. n is also not known wllether nllatidine can · 
cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nllatidine 
should be used during prngnancy only if the potential benefit justifies the potential risk to the fetus. 
Nutsing Mothets-Siudies in lactating women have shown that 0.1% of an oral dose is secreted 
in human milk in proportioo to plasma concentrations. Because of growth depression in pups reared 
by treated lactating rats, a decision should be made whether to d~ntinue nursing or the drug, taking 
into account the importance of the drug to the mother. 
Podiatric Use-Safety and effectiwness in cflildren have not been established. 
Use in Bderly Patients-Healing rates in elderty patients were ~milar to those in yoonger age groups 
as were the rates of ~ events and laboratory terrt abnormalities. Age alone may not be an important 
factor in the diS!lOSitioo of nizatidne. Elderly patients may have reduced renal function. 
Adverse Reactions: Worldwide, controlled dinical ma1s induded ""'r 6,000 patients given nizatidine in 
studies of varying durations. Placebo-controlled trials in the Unrted States and Canada induded over 2,600 patients 
given nizatidine and over t .700 given placebo. Among the adverse events in these ~trolled tri~ only 
anemia (0.2% liS 0%) and urticaria (0.5% liS 0.1%) were significantiy more common in the nizatidine groop. Of 
the adverse events that occurred at a ~equency of 1% or more, there was no stltislically significant difference 
between Axid and placebo in the incidence of any at these events (see package insert for complete information). 
A variety of less common events were also reported; rt was not possible to determine wllelher these 
were caused by nizatidine. 
1/epalic-Hepatoceflular injury (elevated liver enzyme tests Of alkaline pflosiJI!atlse) possibly Of probably 
related to nizatidine occurred in some patients. In some cases, there was marl<ed elevatioo (>500 lUll) in 
SGOT or SGPT and, in a single instance. SGPT was >2,000 lUlL The incidence of elevated liver ellZ)'r110S 
overall and elevations of up to 3 times the upper limrt of normal, however, did not significantly diftef from that 
in placebo patients. All abnO<malities were reversible after discontinuation of Axid. Since marl<et introduction, 
hepatitis and jaundice have been reported. Rare cases of cholestatic or mixed hepatocellular and cholestatic 
injury with jaundice have been reported with reversal of the abllOIITlalities after d~tinualioo of Axid. 
Cardiovascular -In dinical pharmacology studies, sOOrt episodes of asymptomatic ventricular tachycardia 
occurred in 2 individuals administered Axid and in 3 untreated subjocts. 
CNS-Rare cases of reversible mental confusion have been reported. 
Endocline-Ciinical pharmacology studies aAd controlled clinical trials sh!med no evidence of anti-
androgenic activity due to nizatidine. Impotence and decreased libido were reported with similar frequency 
by patients on nizatidlne and those oo placelxl. Gynecomastia has been reported rarely. 
Hematologic-Anemia was reported significanuy mO<e ~equenUy in nizatidine than in placeOO-treated 
patients. Fatal thrombocytopenia was reported in a patient treated with nizatidine and another H2-receptor 
antagonist This patient had previously experienced thrombocytopenia wllile taking othet" drugs. Rare cases 
of thrombocytopenic purpura have been reported. 
Integumental-Urticaria was reported significanUy more ~equeoUy in nizatidine- than in placebo-treated 
patients. Rash and exfoliative dermatitis were also reported. 
Hypersensitivity-As with other H2-recepl0f antagonists, rare cases of anaphyfam following nizatidine 
administration have been reported. Rare episodles of liypefsen~tlvity reactioos (eg, bronchospasm.laryngeal 
edema, rash. and eosiflOf)hilia) have been reported. 
Other-Hyperuricemia unassociated with gout or nephrofrthiasis was reported. Eosinophilia, fever, and 
nausea related to nizatidine have been reported. 
OverdGsage: Overdoses of Axid have been reported rarely. H overdosage occurs, activated cflarcoal. 
emesis, or lavage shoold be considered aloog with clinical monrtoring and supportive ther.!py. The ability of 
hemodialysis to remove nizatidine from the body has not been condusivefy demonstrated; however. due to its 
large volume of d~ibulioo, nizatidine is not expected to be efficiently removed from the body by this method. 
N 2093 AMP (101591] 
Mditional inlorma&an available to the proiBssion an request 
Eli Ully and Company 
Indianapolis, Indiana 
46285 
NZ-2947 -B-249304 '0 1991. EU ULLY AND COMPANY 
HAWAII MEDICAL JOURNAL-VOL. 51, No. I-JANUARY 1992 
HEREDITARY ANEMIA (Continuedfrompage 17) 
11. Hsia YE, Yuen J, Hwll JA, Chu BM, Miyakawa F: Hemoglobin His not a 
disease. Pediatr Res 29:131A, 1991 [#769]. 
12. Hsia Ye, Yuen J, Hunt JA, Ranamanasay P, Hall J, Takaesu N, Titus EAB, 
Fujita J, Ford CA: The different types of alpha-thalassemia: practical and 
genetic aspects. Hemoglobin 12:465-484, 1988. 
13. Ireland JH, Hsia YE, Chui DHK: Anti-zeta testing for alpha-! thalassemia 
in newborns. Pedi.atr Res 29:142A, Abstr 841, 1991. 
14. Ireland JH, Hsia YE, OIUi DHK: Anti-zeta screenign detects the (--SEA) 
double alpha-globin deletion. Ami Hum Genet46:A329, 1991 [1839] . 
15. Then J, Hsia YE: Consumer attitudes toward thalassemia screening: het-
erozygotes of multi-ethnic origin. Am J Hum Genet 46:A331, 1991 [1851]. 
16. Yuen J, Hsia YE: How community resources can be utilized in multi-eth-
nic population screening - a thalassemia screening model. Am J Hum 
Genet42:282A, 1989 #1113. 
17. Yuen J, Hsia YE, Hall J : Impact of a thalassemia screening program on 
the attitudes of a multi-ethnic poulation. In: Bank A (ed): Sixth Cooley's 
Anemia Symposium. New York Acad Sci 612:529-531. 
18. Yuen J, Hsia YE, Hall J: Thalassemia heterozygotes in Hawaii: ethnic atti-
tudes toward screening and prenatal diagnosis. Hemoglobin 12:801-816, 
1988. 
• 
PHARMACEUTICAL (Continuedfrompage 16) 
mission. Intellectual property protection must be 
strengthened, not weakened as in Canada, and tough 
action taken against patent pirates. 
Cut product liability costs. The high cost of protecting 
against the possibility of high jury awards in product 
liability cases adds millions of dollars to drug costs. A 
refonn of the tort laws is needed, including protection 
against punitive damages for products that have been 
deemed safe and effective by the Food and Drug 
Administration. 
Conclusion 
The Senate Aging Committee's staff is singling out one 
competitive industry for price controls and weakened patent 
protection. If their recommendations are enacted, it would 
have a damaging effect on both health care and U.S. interna-
tional competitiveness. 
"ARE YOU SURE YOU'RE TAKING THAT 
VITAMIN PRESCRIPTION?" 
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